Shojaei Amir
Known title: CHIEF SCIENTIFIC OFFICERCIK: 0002051427
Associated companies
Transaction History
| HROW | ▲ Buy | Option Exercise | 11,250 | $405K | 8/14/2026 | View on chart |
| HROW | ▼ Sell | Open Market | 11,250 | $450K | 8/14/2026 | View on chart |
| HROW | ▲ Buy | Option Exercise | 11,250 | $405K | 8/14/2026 | View on chart |
| HROW | ▼ Sell | Open Market | 11,250 | $450K | 8/14/2026 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Harrow (HROW) gains analyst support and conference buzz amid turnaround focus
Recent coverage highlights growing attention on Harrow’s ophthalmic pipeline, with analysts maintaining a $63 price target and an average target of $65. A recent conference has generated buzz, while options activity suggests market participants are watching the stock closely. The company’s Q3 results are expected to confirm whether the turnaround plan is taking hold.
Harrow (HROW) gains analyst support and conference buzz amid turnaround focus. Recent coverage highlights growing attention on Harrow’s ophthalmic pipeline, with analysts maintaining a $63 price target and an average target of $65. A recent conference has generated buzz, while options activity suggests market participants are watching the stock closely. The company’s Q3 results are expected to confirm whether the turnaround plan is taking hold.